V3: an enigmatic isoform of the proteoglycan versican

Author:

Wight Thomas N.1ORCID,Day Anthony J.234,Kang Inkyung1,Harten Ingrid A.1,Kaber Gernot1,Briggs David C.5ORCID,Braun Kathleen R.1,Lemire Joan M.6,Kinsella Michael G.1,Hinek Aleksander7,Merrilees Mervyn J.8

Affiliation:

1. Matrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States

2. Wellcome Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

3. Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

4. Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

5. Signalling and Structural Biology Laboratory, The Francis Crick Institute, London, United Kingdom

6. Department of Biology, Tufts University, Medford, Massachusetts, United States

7. Translational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada

8. Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand

Abstract

V3 is an isoform of the extracellular matrix (ECM) proteoglycan (PG) versican generated through alternative splicing of the versican gene such that the two major exons coding for sequences in the protein core that support chondroitin sulfate (CS) glycosaminoglycan (GAG) chain attachment are excluded. Thus, versican V3 isoform carries no GAGs. A survey of PubMed reveals only 50 publications specifically on V3 versican, so it is a very understudied member of the versican family, partly because to date there are no antibodies that can distinguish V3 from the CS-carrying isoforms of versican, that is, to facilitate functional and mechanistic studies. However, a number of in vitro and in vivo studies have identified the expression of the V3 transcript during different phases of development and in disease, and selective overexpression of V3 has shown dramatic phenotypic effects in “gain and loss of function” studies in experimental models. Thus, we thought it would be useful and instructive to discuss the discovery, characterization, and the putative biological importance of the enigmatic V3 isoform of versican.

Funder

Ann Ramsey-Jenkins and William M. Jenkins Fellowship for Matrix Biology

Medical Research Council

Versus Arthritis

Medical Research Council of New Zealand

National Heart Foundation of New Zealand

University of Auckland

Auckland Medical Research Foundation

HHS | National Institutes of Health

Publisher

American Physiological Society

Subject

Cell Biology,Physiology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3